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Acquired reactive perforating collagenosis
(ARPC) is a type of perforating disorder that is often
associated with underlying systemic diseases, such
as diabetes mellitus, renal failure, or malignancy.
Giant variants of ARPC may reach up to 2 cm in size
and have been reported in only a handful of cases.
We present a patient with giant ARPC in the setting of
metastatic breast cancer and uncontrolled diabetes
mellitus.CASE REPORT
A 46-year-old woman presented with a 3-month
history of nonpruritic, nontender, hyperkeratotic
papules and plaques that involved the upper and
lower extremities. She recently had a diagnosis of de
novo metastatic hormone receptorepositive breast
cancer involving the brain, liver, bone, and lymph
nodes and uncontrolled diabetes mellitus. She
received dexamethasone, whole-brain radiation,
tamoxifen, leuprolide, and insulin with excellent
control of metastatic disease and diabetes. The
patient was referred to the dermatology department
from her oncologist to rule out disseminated zoster,
as she had significant lymphopenia from long-term
steroid use.
On examination, discrete, erythematous, umbi-
licated papules and plaques with central, adherent,
1- to 2-cm hyperkeratotic cores were seen on
the upper and lower extremities (Fig 1, A).
Koebnerization was apparent on the forearms (Fig
1, B). Laboratory analysis found a normal creatininethe Ronald O. Perelman Department of Dermatologya and
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umc.org.level of 0.48 mg/dL, an elevated glucose level of
217mg/dL, and a hemoglobin A1c of 11.5%. A punch
biopsy of a lesion on the lower extremity was
performed.
Histologic analysis found a large epidermal ulcer
with overlying prominent scale crust. Vertically
oriented, brightly eosinophilic collagen fibers were
seen in the dermis, epidermis, and scale crust (Fig 2),
confirming the diagnosis of ARPC.
Because of her concurrent cancer therapies, the
patient declined any dermatologic intervention for
her lesions. However, after 10 months of glycemic
control and chemotherapy, her lesions were
significantly improved, with resolution of the
hyperkeratotic cores and residual postinflammatory
hyperpigmented macules (Fig 3).DISCUSSION
Reactive perforating collagenosis (RPC) is a type
of perforating disorder in which degenerated
collagen is transepidermally eliminated. Although
initially described as a childhood disorder,1 acquired
adult RPC has been reported2 particularly in
association with underlying systemic disease.
Clinically, the lesions appear as erythematous-to-
hyperpigmented papules, plaques, and nodules withJAAD Case Reports 2016;2:22-4.
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Fig 1. Giant ARPC. A, Erythematous, umbilicated papules and plaques with central adherent
thick hyperkeratotic cores are seen on the upper and lower extremities. Representative lesions
are seen on her left lateral thigh. The largest keratotic cores measure up to 2 cm. B, Evidence of
koebnerization on the forearm.
Fig 2. Histopathologic sections from punch biopsy
specimen. A large epidermal ulcer is evident with
vertically oriented collagen fibers (arrow) extruding
from the dermis into the overlying thick scale-crust.
(Hematoxylin-eosin stain.)
Fig 3. Resolving lesions of reactive perforating collage-
nosis after 10 months of glycemic control. Residual
postinflammatory hyperpigmented macules at the site of
prior lesions on the left lateral thigh.
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core. The lesions are commonly pruritic and exhibit
koebnerization. ARPC typically is distributed on the
extensor aspects of the extremities, trunk, buttocks,
and occasionally the face.3 Rare variants include
giant lesions that measure 1 to 2 cm.4
Histopathologic features include a central crater,
with epidermal ulceration and extrusion of vertically
oriented connective tissue elements, such as
collagen, keratin, and debris. A hyperkeratotic crust
may overlie the ulcer.3
The differential diagnosis for ARPC largely
encompasses other perforating disorders, such as
perforating folliculitis, elastosis perforans serpigi-
nosa, and Kyrle’s disease. A more generalized
term, acquired perforating dermatosis, is sometimes
used to refer to such cases that occur in adults
with systemic disease. The clinical spectrum of
acquired perforating dermatosis includes ery-
thematous follicular papules and pustules (perfo-
rating folliculitiselike), hyperkeratotic papules and
nodules (Kyrle’s diseaseelike), and umbilicatedpapules with keratotic plugs (RPC-like).5
Therefore, histologic analysis is necessary to identify
the perforating element.
Although the pathogenesis is unknown, superfi-
cial trauma and diabetic microvasculopathy6 are
hypothesized to be contributing factors to ARPC. In
a review of approximately 100 cases, 62% were
associated with diabetes mellitus and its complica-
tions.3 In 4 reported patients with giant ARPC, 3 had
coexisting diabetes mellitus.4 ARPC is also associated
with malignant conditions including leukemia,
lymphoma, prostate carcinoma, hepatobiliary
carcinomas, and papillary thyroid cancer.3 In at least
2 cases, ARPC developed in patients with diabetes
mellitus and malignancy.7 Breast cancereassociated
ARPC has never been reported in literature. Although
our patient’s ARPC is most likely associated with
diabetes mellitus, we cannot exclude the possibility
of an association between ARPC and breast cancer.
Treatments include topical glucocorticoids,
topical and oral retinoids, oral antibiotics, and
ultraviolet-B phototherapy, although the efficacy is
often varied or unsatisfactory.3 Lesions may improve
after treatment of the coexisting systemic condition.
In our patient, her lesions dramatically improved
with insulin and chemotherapy. As her cancer
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improvement of her ARPC with better glycemic
control. Recently, allopurinol has been used
successfully, particularly in the setting of diabetes
mellitus8 and in giant ARPC.4 It is proposed that
allopurinol may inhibit collagen cross-linking that is
elevated in hyperglycemic states and may inhibit
xanthine oxidase to decrease reactive oxygen
species formation that leads to damaged collagen.8
In reported cases of giant ARPC, allopurinol 100 mg
daily for 2 to 4 months resulted in appreciable
improvement in pruritus and the number of lesions4
and is a reasonable treatment option to consider in
such cases.
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